ID

31068

Descrizione

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00384150

collegamento

https://clinicaltrials.gov/show/NCT00384150

Keywords

  1. 17/07/18 17/07/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

17 luglio 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :


Non ci sono commenti

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Non-Hodgkin Lymphoma NCT00384150

Eligibility Non-Hodgkin Lymphoma NCT00384150

Criteria
Descrizione

Criteria

demonstrated a response (cr, cru, or pr) on study 114-nh-301 (galiximab in combination with rituximab compared with rituximab in combination with placebo) and then relapsed or progressed with a ttp >=6 months. relapsed disease is defined as documented disease progression using the international workshop response criteria (iwrc).
Descrizione

Disease Response | In complete remission | Complete remission Uncertain | Partial response | galiximab/rituximab | Rituximab Placebo Combined | Recurrent disease | Disease Progression | Time to Progression

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1704632
UMLS CUI [2]
C0677874
UMLS CUI [3,1]
C0677874
UMLS CUI [3,2]
C0087130
UMLS CUI [4]
C1521726
UMLS CUI [5]
C1327912
UMLS CUI [6,1]
C0393022
UMLS CUI [6,2]
C1696465
UMLS CUI [6,3]
C0205195
UMLS CUI [7]
C0277556
UMLS CUI [8]
C0242656
UMLS CUI [9]
C2985467
bidimensionally measurable disease with at least 1 lesion >=2.0 cm in a single dimension.
Descrizione

Measurable Disease 2-Dimensional | Lesion Size Linear Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1705052
UMLS CUI [2,1]
C0221198
UMLS CUI [2,2]
C0456389
UMLS CUI [2,3]
C0205132
UMLS CUI [2,4]
C1265611
acceptable hematologic, hepatic, and renal function.
Descrizione

Hematologic function | Liver function | Renal function

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
key exclusion criteria:
Descrizione

Exclusion Criteria Main

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
any lymphoma therapy between final visit on study 114-nh-301 and study day 1 of this retreatment study.
Descrizione

Therapeutic procedure Lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0024299
chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to study day 1.
Descrizione

Adrenal Cortex Hormones chronic Inflammatory disorder | Adrenal Cortex Hormones chronic Autoimmune Diseases | Adrenal Cortex Hormones Intermittent Inflammatory disorder | Adrenal Cortex Hormones Intermittent Autoimmune Diseases

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0205191
UMLS CUI [1,3]
C1290884
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C0205191
UMLS CUI [2,3]
C0004364
UMLS CUI [3,1]
C0001617
UMLS CUI [3,2]
C0205267
UMLS CUI [3,3]
C1290884
UMLS CUI [4,1]
C0001617
UMLS CUI [4,2]
C0205267
UMLS CUI [4,3]
C0004364
transfusion-dependent subjects.
Descrizione

Study Subject Transfusion dependent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0681850
UMLS CUI [1,2]
C1698624
presence of central nervous system (cns) lymphoma.
Descrizione

Central nervous system lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0742472
histologic transformation.
Descrizione

Transformation Histologic

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0040682
UMLS CUI [1,2]
C0205462
presence of pleural or peritoneal effusion with positive cytology for lymphoma.
Descrizione

Pleural effusion | Peritoneal effusion | Positive Cytology Lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032227
UMLS CUI [2]
C0003964
UMLS CUI [3,1]
C3846509
UMLS CUI [3,2]
C0024299
another primary malignancy requiring active treatment.
Descrizione

Primary tumor Treatment required for

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0677930
UMLS CUI [1,2]
C0332121
serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions that would compromise protocol objectives in the opinion of the investigator and/or the sponsor.
Descrizione

Disease Serious Non-Malignant | Congestive heart failure | Hydronephrosis | Bacterial Infections Uncontrolled | Virus Diseases Uncontrolled | Mycoses Uncontrolled | Condition compromises Study Protocol

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C1518371
UMLS CUI [2]
C0018802
UMLS CUI [3]
C0020295
UMLS CUI [4,1]
C0004623
UMLS CUI [4,2]
C0205318
UMLS CUI [5,1]
C0042769
UMLS CUI [5,2]
C0205318
UMLS CUI [6,1]
C0026946
UMLS CUI [6,2]
C0205318
UMLS CUI [7,1]
C0348080
UMLS CUI [7,2]
C2945640
UMLS CUI [7,3]
C2348563
new york heart association class iii or iv cardiac disease or myocardial infarction within 6 months prior to study day 1.
Descrizione

Heart Disease New York Heart Association Classification | Myocardial Infarction

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0018799
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C0027051

Similar models

Eligibility Non-Hodgkin Lymphoma NCT00384150

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
Disease Response | In complete remission | Complete remission Uncertain | Partial response | galiximab/rituximab | Rituximab Placebo Combined | Recurrent disease | Disease Progression | Time to Progression
Item
demonstrated a response (cr, cru, or pr) on study 114-nh-301 (galiximab in combination with rituximab compared with rituximab in combination with placebo) and then relapsed or progressed with a ttp >=6 months. relapsed disease is defined as documented disease progression using the international workshop response criteria (iwrc).
boolean
C1704632 (UMLS CUI [1])
C0677874 (UMLS CUI [2])
C0677874 (UMLS CUI [3,1])
C0087130 (UMLS CUI [3,2])
C1521726 (UMLS CUI [4])
C1327912 (UMLS CUI [5])
C0393022 (UMLS CUI [6,1])
C1696465 (UMLS CUI [6,2])
C0205195 (UMLS CUI [6,3])
C0277556 (UMLS CUI [7])
C0242656 (UMLS CUI [8])
C2985467 (UMLS CUI [9])
Measurable Disease 2-Dimensional | Lesion Size Linear Quantity
Item
bidimensionally measurable disease with at least 1 lesion >=2.0 cm in a single dimension.
boolean
C1513041 (UMLS CUI [1,1])
C1705052 (UMLS CUI [1,2])
C0221198 (UMLS CUI [2,1])
C0456389 (UMLS CUI [2,2])
C0205132 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
Hematologic function | Liver function | Renal function
Item
acceptable hematologic, hepatic, and renal function.
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Therapeutic procedure Lymphoma
Item
any lymphoma therapy between final visit on study 114-nh-301 and study day 1 of this retreatment study.
boolean
C0087111 (UMLS CUI [1,1])
C0024299 (UMLS CUI [1,2])
Adrenal Cortex Hormones chronic Inflammatory disorder | Adrenal Cortex Hormones chronic Autoimmune Diseases | Adrenal Cortex Hormones Intermittent Inflammatory disorder | Adrenal Cortex Hormones Intermittent Autoimmune Diseases
Item
chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to study day 1.
boolean
C0001617 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C1290884 (UMLS CUI [1,3])
C0001617 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0004364 (UMLS CUI [2,3])
C0001617 (UMLS CUI [3,1])
C0205267 (UMLS CUI [3,2])
C1290884 (UMLS CUI [3,3])
C0001617 (UMLS CUI [4,1])
C0205267 (UMLS CUI [4,2])
C0004364 (UMLS CUI [4,3])
Study Subject Transfusion dependent
Item
transfusion-dependent subjects.
boolean
C0681850 (UMLS CUI [1,1])
C1698624 (UMLS CUI [1,2])
Central nervous system lymphoma
Item
presence of central nervous system (cns) lymphoma.
boolean
C0742472 (UMLS CUI [1])
Transformation Histologic
Item
histologic transformation.
boolean
C0040682 (UMLS CUI [1,1])
C0205462 (UMLS CUI [1,2])
Pleural effusion | Peritoneal effusion | Positive Cytology Lymphoma
Item
presence of pleural or peritoneal effusion with positive cytology for lymphoma.
boolean
C0032227 (UMLS CUI [1])
C0003964 (UMLS CUI [2])
C3846509 (UMLS CUI [3,1])
C0024299 (UMLS CUI [3,2])
Primary tumor Treatment required for
Item
another primary malignancy requiring active treatment.
boolean
C0677930 (UMLS CUI [1,1])
C0332121 (UMLS CUI [1,2])
Disease Serious Non-Malignant | Congestive heart failure | Hydronephrosis | Bacterial Infections Uncontrolled | Virus Diseases Uncontrolled | Mycoses Uncontrolled | Condition compromises Study Protocol
Item
serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions that would compromise protocol objectives in the opinion of the investigator and/or the sponsor.
boolean
C0012634 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C1518371 (UMLS CUI [1,3])
C0018802 (UMLS CUI [2])
C0020295 (UMLS CUI [3])
C0004623 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0042769 (UMLS CUI [5,1])
C0205318 (UMLS CUI [5,2])
C0026946 (UMLS CUI [6,1])
C0205318 (UMLS CUI [6,2])
C0348080 (UMLS CUI [7,1])
C2945640 (UMLS CUI [7,2])
C2348563 (UMLS CUI [7,3])
Heart Disease New York Heart Association Classification | Myocardial Infarction
Item
new york heart association class iii or iv cardiac disease or myocardial infarction within 6 months prior to study day 1.
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C0027051 (UMLS CUI [2])

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial